Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Senior Vice President and CFO William R. LaRue will present a corporate overview on Thursday, March 20, 2008 at 11:00am Eastern Time (8:00am Pacific Time) during the Cowen and Company 28th Annual Health Care Conference at the Marriott Copley Place in Boston, Massachusetts.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com/. To access the presentation, click on the Investor Relations tab and then click on the link entitled "Events and Presentations" on the left side of the screen. A replay of the webcast will available approximately one hour after the live webcast concludes and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com/.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue
SVP & Chief Financial Officer
Cadence Pharmaceuticals, Inc.
858-436-1400

Anna Gralinska
Director, Investor Relations
Cadence Pharmaceuticals, Inc.
(858) 436-1452

First Call Analyst:
FCMN Contact: shogan@cadencepharm.com

Source: Cadence Pharmaceuticals, Inc.

CONTACT: William R. LaRue, SVP & Chief Financial Officer,
+1-858-436-1400, or Anna Gralinska, Director, Investor Relations,
+1-858-436-1452, both of Cadence Pharmaceuticals, Inc.

Web site: http://www.cadencepharm.com/

2008-03-13 18:02:14 0312422 PRNEWSWIRE